```
     (FILE 'HOME' ENTERED AT 13:50:55 ON 13 NOV 2003)

     FILE 'CAPLUS' ENTERED AT 13:51:06 ON 13 NOV 2003
L1      1616682 S CALCIUM CHANNEL (2A) BLOCK? OR INHIBIT?
L2         8110 S CALCIUM CHANNEL (2A) (BLOCK? OR INHIBIT?)
L3            1 S L2 AND (MYOFIBROBLAST)
L4           95 S L2 AND (MUSCLE RELAX?)
L5          102 S L2 AND (MUSCLE (1A) RELAX?)
L6           35 S L2 (1S) (MUSCLE (1A) RELAX?)
L7            0 S L6 AND (FACIAL OR FACE OR ?FACIAL)
L8            0 S L6 AND (STRIATE?)

     FILE 'USPATFULL' ENTERED AT 13:54:13 ON 13 NOV 2003

     FILE 'USPATFULL, CAPLUS' ENTERED AT 13:54:17 ON 13 NOV 2003
L9          522 FILE USPATFULL
L10          35 FILE CAPLUS
     TOTAL FOR ALL FILES
L11         557 S L6
L12           2 FILE USPATFULL
L13           0 FILE CAPLUS
     TOTAL FOR ALL FILES
L14           2 S L11 AND (STRIATED)
L15           3 FILE USPATFULL
L16           0 FILE CAPLUS
     TOTAL FOR ALL FILES
L17           3 S L6 AND (DERMAL FIBROBLAST?)
L18           0 FILE USPATFULL
L19           0 FILE CAPLUS
     TOTAL FOR ALL FILES
L20           0 S L2 (1S) ((MOTO NEURON?) OR MYONEUR?)
L21           8 FILE USPATFULL
L22           2 FILE CAPLUS
     TOTAL FOR ALL FILES
L23          10 S L2 (1S) ((MOTOR NEURON?) OR MYONEUR?)
L24           8 FILE USPATFULL
L25           0 FILE CAPLUS
     TOTAL FOR ALL FILES
L26           8 S FACE AND WRINKLE AND HYPERCONTRACTION AND MUSCLE
L27          22 FILE USPATFULL
L28          59 FILE CAPLUS
     TOTAL FOR ALL FILES
L29          81 S CONTRACTILE FIBER
L30           0 FILE USPATFULL
L31           0 FILE CAPLUS
     TOTAL FOR ALL FILES
L32           0 S L2 (1S) L29
L33           2 FILE USPATFULL
L34           1 FILE CAPLUS
     TOTAL FOR ALL FILES
L35           3 S L2 AND L29
```

L11 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1983:502908 CAPLUS
DN 99:102908
TI Comparative studies of collagen lattice contraction utilizing a normal and a transformed cell line
AU Buttle, David J.; Ehrlich, H. Paul
CS Shriner Burns Inst., Massachusetts Gen. Hosp., Boston, MA, 02114, USA
SO Journal of Cellular Physiology (1983), 116(2), 159-66
CODEN: JCLLAX; ISSN: 0021-9541
DT Journal
LA English
CC 13-6 (Mammalian Biochemistry)
Section cross-reference(s): 14
AB Differences between the behavior of cultured rat **skin** fibroblasts and that of a line of transformed rat sarcoma cells incorporated into a polymd. collagen lattice were examd. Fibroblast-populated collagen lattices (FPCL) were manufd. Within 24-48 h after manuf., both cell lines reduced lattice size by a process known as lattice contraction. Contraction occurred more rapidly in both cell lines when the media were supplemented with 25% serum rather than the usual concn. of 10% serum. Similar growth patterns were obsd. with transformed cells within collagen lattices and on plastic surfaces. Normal rat fibroblasts contracted lattices faster than transformed cells. At the end of a 2-wk period, the final contracted size of the transformed cell lattice was the same as that of normal cell lattices. The cellular d. of transformed cells within the FPCL was 8-fold greater than that of FPCL made with normal rat cells. Normal rat fibroblasts elongated and flattened more, and organized the collagen matrix to a greater degree, than did transformed cells. In this instance, therefore, lattice **contraction** is linked more to the process of fibroblast elongation and **collagen fiber** organization than to cell no. or d.
ST collagen lattice contraction fibroblast sarcoma; **tissue** culture fibroblast sarcoma collagen
IT Blood serum
(collagen lattice contraction by fibroblasts and transformed cells in culture stimulation by)
IT Transformation, neoplastic
(collagen lattice contraction by mammalian cell lines in relation to)
IT Sarcoma
(collagen lattice contraction response to transformed, in culture, cell growth in relation to)
IT Fibroblast
(collagen lattice contraction response to, in culture)
IT Animal **tissue** culture
(fibroblast and transformed sarcoma cell growth in, in fibroblast-populated collagen lattices)
IT Collagens, biological studies
RL: BIOL (Biological study)
(fibroblast-populated lattices of, contraction of, by growth of fibroblast and transformed sarcoma cells)
IT Cell division
(mitosis, by fibroblasts in transformed sarcoma cells in culture, growth in fibroblast-populated collagen lattices in relation to)

L11 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:770309 CAPLUS
DN 136:382356
TI Two-photon imaging of collagen remodeling in RAFT **tissue** cultures
AU Wallace, Vincent P.; Coleno, Mariah L.; Yomo, Tatsuro; Sun, Chung-Ho; Tromberg, Bruce J.
CS Laser Microbeam and Medical Program (LAMMP), Beckman Laser Institute, University of California, Irvine, CA, 92612, USA
SO Proceedings of SPIE-The International Society for Optical Engineering (2001), 4262(Multiphoton Microscopy in the Biomedical Sciences), 118-124
CODEN: PSISDG; ISSN: 0277-786X
PB SPIE-The International Society for Optical Engineering
DT Journal
LA English
CC 9-5 (Biochemical Methods)
AB **Tissue** remodeling is assocd. with both normal and abnormal processes including wound healing, fibrosis and cancer. In **skin**, abnormal remodeling causes permanent structural changes that can lead to hypertrophic scarring and keloid formation. Normal remodeling, although fast and efficient in **skin**, is still imperfect, and a connective **tissue** scar remains at the wound site. As a result, methods are needed to optimize **tissue** remodeling in vivo in all cases of wound repair. Since fibroblast-mediated contraction of engineered 3-D. collagen based **tissues** (RAFTs) represents an in vitro model of the **tissue** contraction and collagen remodeling that occurs in vivo, RAFT **tissue** contraction studies combined with two-photon microscopy (TPM) studies are used to provide information on ways to improve **tissue** remodeling in vivo. In the RAFT models discussed here, **tissue** contraction is modulated either by application of exogenous growth factors or photodynamic therapy. During **tissue contraction**, TPM is used to image changes in **Collagen** Type I **fibers** in the RAFT **skin** models. **Tissues** are imaged at depth at day 15 after modulation. TPM signal anal. shows that RAFT **tissues** having the highest collagen d. have the fastest rate of decay of fluorescent signal with depth.
ST collagen remodeling RAFT **tissue** model 2 photon imaging; wound healing model transforming growth factor photodynamic therapy
IT **Skin**
(artificial **tissue** model (RAFT); two-photon imaging of collagen remodeling in RAFT **tissue** cultures)
IT Photodynamic therapy
Simulation and Modeling, biological
Wound healing
(two-photon imaging of collagen remodeling in RAFT **tissue** cultures)
IT Microscopy
(two-photon; two-photon imaging of collagen remodeling in RAFT **tissue** cultures)
IT Collagens, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type I, fibers; two-photon imaging of collagen remodeling in RAFT **tissue** cultures)
IT Transforming growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.beta.-; two-photon imaging of collagen remodeling in RAFT **tissue** cultures)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Agarwal, A; Tissue Engineering, In press
(2) Coleno, M; SPIE Proceedings 1999, V3604, P67 CAPLUS
(3) Dunn, A; Applied Optics 2000, V39(7), P1194
(4) Henderson, B; Photodynamic therapy:Basic principles and clinical

applications 1992
(5) Martin, P; Science 1997, V276, P75 CAPLUS
(6) Montesano, R; Proc Natl Academy of Sciences 1988, P4894 CAPLUS

L21 ANSWER 19 OF 35 USPATFULL on STN

DETD This example shows that factors in cheese whey extract act on the human **skin** fibroblast to induce reorganization of **collagen fibers** and **contraction** of a collagen gel that is analogous to the **contraction** of a wound.

ACCESSION NUMBER:	2001:208501 USPATFULL
TITLE:	Growth-promoting agent
INVENTOR(S):	Ballard, Francis John, Kensington, Australia Francis, Geoffrey Leonard, Athelstone, Australia Regester, Geoffrey Owen, Ferntree Gully, Australia Read, Leanna Christine, Kensington, Australia Belford, David Andrew, Seacliff Park, Australia
PATENT ASSIGNEE(S):	GroPep Limited, Australia (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6319522	B1	20011120	
APPLICATION INFO.:	US 1998-82987		19980522	(9)

L21 ANSWER 17 OF 35 USPATFULL on STN

SUMM The mechanical properties of the **skin**, such as elasticity, are controlled by the density and geometry of the network of **collagen** and elastic **fiber** tissue therein. Damaged collagen and elastin lose their **contractile** properties, resulting in **skin** wrinkling and **skin** surface roughness. As the **skin** ages or becomes unhealthy, it acquires sags, stretch marks, bumps, braises or wrinkles, it roughens, and it has reduced ability to synthesize Vitamin D. Aged **skin** also becomes thinner and has a flattened dermoepidermal interface because of the alterations in collagen, elastin, and glycosaminoglycans. [Fenske, N. A, and Lober, C. W., J. Am. Acad. Dermatol., 15:571-585 (Oct. 1986); Montagna, W. and Carlisle, K., Journal of investigative Dermatol., 73(1):47-53 (1979)].

ACCESSION NUMBER:	2002:57416 USPATFULL
TITLE:	Pharmaceutical compositions for reducing the appearance of cellulite
INVENTOR(S):	Murad, Howard, 4265 Marina City Dr., Marina del Rey, CA, United States 90292

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6358539	B1	20020319	
APPLICATION INFO.:	US 2000-641376		20000818	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-150034P	19990820	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Tate, Christopher R.
ASSISTANT EXAMINER:	Flood, Michele C.
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP
NUMBER OF CLAIMS:	16
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	1426

L26 ANSWER 1 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2003:92727 USPATFULL
TITLE: Cosmetic or dermatological composition comprising a combination of an elastase inhibitor of the N-acylaminoamide family and at least one myorelaxing agent
INVENTOR(S): Breton, Lionel, Versailles, FRANCE
PATENT ASSIGNEE(S): L'OREAL, Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003064085	A1	20030403
APPLICATION INFO.:	US 2002-179984	A1	20020626 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2001-8436	20010626

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC, FOURTH FLOOR, 1755 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 1242
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 2 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2002:112940 USPATFULL
TITLE: Treating skin **wrinkles**/fine lines with calcium channel inhibitors
INVENTOR(S): Breton, Lionel, Versailles, FRANCE
Nonotte, Isabelle, Paris, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002058682	A1	20020516
APPLICATION INFO.:	US 2001-981751	A1	20011019 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-572234, filed on 17 May 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1999-6290	19990518

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Norman H. Stepno, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 508
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 3 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2002:48063 USPATFULL
TITLE: Manganese compositions for reducing/preventing skin **wrinkles** and fine lines
INVENTOR(S): Nonotte, Isabelle, Paris, FRANCE
Breton, Lionel, Versailles, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002028254	A1	20020307

APPLICATION INFO.: US 2001-859384 A1 20010518 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2000-6373	20000518

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Norman H. Stepno, Esquire, BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 592
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 4 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2002:24290 USPATFULL
TITLE: Treating skin **wrinkles**/fine lines with calcium channel inhibitors
INVENTOR(S): Breton, Lionel, Versailles, FRANCE
Nonotte, Isabelle, Paris, FRANCE
PATENT ASSIGNEE(S): Societe L'Oreal S.A., Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6344461	B1	20020205
APPLICATION INFO.:	US 2000-572234		20000517 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1999-6290	19990518

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Jarvis, William R. A.
ASSISTANT EXAMINER: Kim, Vickie
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 442
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 5 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2002:1260 USPATFULL
TITLE: Use of alverine for reducing **wrinkles**
INVENTOR(S): Liviero, Christel, Paris, FRANCE
Breton, Lionel, Versailles, FRANCE
Pineau, Nathalie, Poitiers, FRANCE
PATENT ASSIGNEE(S): Societe L'Oreal S.A., Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6335368	B1	20020101
APPLICATION INFO.:	US 2000-666343		20000921 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1999-11772	19990921

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Henley, III, Raymond
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.

NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 6 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2001:63228 USPATFULL
TITLE: Antiwrinkle cosmetic/pharmaceutical compositions comprising iridaceae extracts
INVENTOR(S): Breton, Lionel, Versailles, France
De Lacharriere, Oliver, Paris, France
Martin, Richard, Rochecorbon, France
PATENT ASSIGNEE(S): Societe L'Oreal S.A., Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6224850	B1	20010501
APPLICATION INFO.:	US 1997-826424		19970327 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1996-3817	19960327

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Seidleck, Brian K.
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 677

L26 ANSWER 7 OF 8 USPATFULL on STN
ACCESSION NUMBER: 1999:136709 USPATFULL
TITLE: Compositions and methods for treating **wrinkles** and/or fine lines of the skin
INVENTOR(S): De Lacharriere, Olivier, Paris, France
Breton, Lionel, Versailles, France
PATENT ASSIGNEE(S): L'Oreal, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5976559		19991102
APPLICATION INFO.:	US 1998-50959		19980331 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-538119, filed on 2 Oct 1995, now patented, Pat. No. US 5869068

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1994-11742	19940930

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Venkat, Jyothsna
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1,7,13,19,25
LINE COUNT: 500
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 8 OF 8 USPATFULL on STN
ACCESSION NUMBER: 1999:18740 USPATFULL
TITLE: Compositions and methods for treating **wrinkles** and/or fine lines of the skin

INVENTOR(S):	De Lacharriere, Olivier, Paris, France Breton, Lionel, Versailles, France		
PATENT ASSIGNEE(S):	L'Oreal, Paris, France (non-U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5869068		19990209
APPLICATION INFO.:	US 1995-538119		19951002 (8)
	NUMBER		DATE
PRIORITY INFORMATION:	FR 1994-11742		19940930
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Venkat, Jyothsna		
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.		
NUMBER OF CLAIMS:	34		
EXEMPLARY CLAIM:	1,8,15,22,29		
LINE COUNT:	591		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.